Curis (NASDAQ:CRIS) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Curis (NASDAQ:CRIS) in a report released on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reduced their price target on Curis from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Monday, March 31st.

Curis Stock Performance

NASDAQ:CRIS opened at $1.89 on Thursday. The company has a market capitalization of $16.04 million, a P/E ratio of -0.24 and a beta of 3.65. The stock’s 50 day moving average price is $2.00 and its 200 day moving average price is $3.08. Curis has a 52 week low of $1.02 and a 52 week high of $16.80.

Curis (NASDAQ:CRIS) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.14) by ($0.11). Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%. The business had revenue of $2.38 million for the quarter, compared to analyst estimates of $2.37 million. During the same quarter last year, the company earned ($2.05) EPS. As a group, sell-side analysts forecast that Curis will post -7.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CRIS. Focused Wealth Management Inc lifted its holdings in shares of Curis by 9.5% during the fourth quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock worth $181,000 after buying an additional 5,138 shares during the last quarter. Squarepoint Ops LLC bought a new position in Curis during the fourth quarter worth $35,000. Millennium Management LLC raised its stake in Curis by 92.6% during the 4th quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 12,287 shares during the last quarter. XTX Topco Ltd bought a new stake in Curis in the 1st quarter valued at $27,000. Finally, Geode Capital Management LLC grew its position in Curis by 27.3% in the 4th quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock worth $254,000 after purchasing an additional 17,820 shares during the last quarter. 29.97% of the stock is currently owned by institutional investors and hedge funds.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.